Diabetes Remote Management

Diabetes is one of the conditions where remote care has produced the clearest gains: continuous glucose monitor (CGM) data shared directly with a clinician, insulin titration through messaging, faster medication adjustments than the in-person visit cadence allowed, and structured nutrition support. The American Diabetes Association's annual Standards of Care explicitly recognize telehealth as part of contemporary diabetes management. This page covers what good remote diabetes care looks like.

The short version

CGM data sharing with a provider, through manufacturer apps and clinician dashboards, is the central technology of modern remote diabetes care.
Time in range, time below range, and trend data matter as much as A1c — and they are visible in real time.
Most insulin titration can be done remotely, often through messaging between visits.
A1c can be done at a local lab on a standing order; many remote endocrinology programs send orders to local draw sites.
An integrated program includes a clinician, a diabetes educator, nutrition support, and access between visits.
Remote care does not eliminate the need for periodic in-person care: foot exams, eye exams, kidney screening, and complications evaluation.

The CGM transformation

Continuous glucose monitors attach to the back of the upper arm or abdomen and report glucose readings every few minutes through a phone or reader. Major manufacturers (Dexcom, Abbott, Medtronic among others) have clinician-side dashboards that allow a provider to see a patient's data with the patient's authorization. The shared data includes time in range, time above and below range, glucose variability, and patterns by time of day.

What this enables: a clinician can adjust an insulin regimen based on actual glucose patterns over weeks rather than a fingerstick log brought to a visit, can see what is happening overnight (the part patients see least), and can identify behavioral patterns that explain hard-to-fit data. CGM has shifted diabetes care from periodic snapshots to continuous data, and telehealth is the natural delivery mode for this shift.

Sharing setup

Each CGM manufacturer has its own data-sharing pathway. The patient typically authorizes a clinician's office through an app or invitation code; the clinician then sees the data through a separate clinician portal. Setting this up before the first visit means the clinician can come in already familiar with your data. CGM categories are evolving — some products are now available over the counter for adults without diabetes; the diagnostic value of CGM in non-diabetic adults remains contested in the medical literature.

Insulin titration by messaging

For people on insulin, dose adjustments often happen between formal visits. A remote diabetes practice may use secure messaging to handle this: the patient reports food, activity, glucose patterns; the clinician adjusts basal or bolus dosing in small increments and follows up. This faster cadence often gets people to target ranges more quickly than the traditional every-three-month visit cadence. It requires patient engagement and a clinician with capacity to do this work.

Insulin pump and automated insulin delivery (AID) systems integrate CGM with insulin pumps and adjust basal rates automatically. These have specific configuration parameters that a clinician can adjust remotely with shared access to the data.

A1c and other labs

A1c (hemoglobin A1c, a measure of average glucose over roughly three months) is still relevant alongside CGM data. It is a lab test that requires a venous or capillary blood draw, not a home device for most clinical purposes. A remote endocrinology practice typically sends a lab order to a draw site near the patient — a national chain (Quest, Labcorp) or a local clinic. Other diabetes-relevant labs follow the same pattern: lipid panel, kidney function (eGFR and urine albumin-to-creatinine ratio), liver function, vitamin D, and others.

Some patients have access to home A1c kits. These are useful as supplements but the clinical standard is laboratory testing. Confirm with your clinician whether a home A1c is acceptable for their decisions.

The integrated program

Diabetes care benefits from a team. A reasonable remote diabetes program includes:

A prescribing clinician — endocrinologist, primary care, or qualified NP/PA — managing medications.
A certified diabetes care and education specialist (CDCES) for diabetes education and self-management training.
A registered dietitian for nutrition guidance.
Access between visits through messaging, with clear response times.
Coordination with primary care and other specialists (ophthalmology, podiatry, nephrology) for the in-person components.
Clear policies for after-hours and emergencies (severe hypoglycemia, suspected diabetic ketoacidosis).

A "diabetes app" that pings you with reminders is not a clinical program. A clinical program has clinicians, scheduled visits, and accountability for outcomes.

What still needs to happen in person

Diabetes complications screening is largely in-person work. Annual dilated eye exam by an ophthalmologist or optometrist screens for diabetic retinopathy. Annual foot exam by a clinician (with monofilament testing for sensation) screens for neuropathy. Kidney function and urine albumin testing usually goes through a local lab but the interpretation is best with a primary care or endocrinology relationship. Some practices do home retinal photography and remote interpretation; this is a useful screening alternative in some settings but not universal.

For type 1 diabetes, annual review of pump and CGM technique benefits from in-person interaction at least periodically. For type 2 diabetes with cardiovascular complications, coordination with cardiology often requires in-person work.

Standards of care

The American Diabetes Association publishes annually updated Standards of Care that are the most-cited reference in diabetes management. They cover diagnosis, glucose targets (with individualization), medication classes (metformin, GLP-1 receptor agonists, SGLT2 inhibitors, insulin, others), cardiovascular risk reduction, kidney protection, and complications screening. Telehealth is recognized in current Standards as a delivery mode for many components of care, with appropriate attention to its limits.

The medication landscape has shifted substantially in recent years. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide) and SGLT2 inhibitors (empagliflozin, dapagliflozin, others) have become first-line in many type 2 diabetes scenarios, often before or alongside metformin, particularly when cardiovascular or kidney protection is a goal. Remote diabetes services that have not updated their default regimens to reflect this evolution are out of step. See GLP-1 weight loss telehealth for the related (but distinct) GLP-1 weight loss space.

Cost and insurance

CGMs, insulin, and many newer diabetes medications are expensive at retail. Insurance coverage varies; Medicare covers CGMs for many beneficiaries; Medicaid coverage varies by state. Some remote diabetes programs work as cash-pay specialty practices; others are integrated with primary care and bill through insurance. Check coverage explicitly before signing up. See insurance and telehealth.

What to look for in a service

A real clinician (endocrinologist, primary care, or qualified NP/PA) responsible for medication decisions, with credentials you can verify.
Diabetes education by a CDCES, not just app content.
Nutrition support by a registered dietitian when needed.
CGM data sharing built into the workflow.
Messaging with a defined response time.
Coordination with primary care, ophthalmology, and podiatry.
Up-to-date practice — current standards include GLP-1s and SGLT2s where indicated.
Clear after-hours and emergency policy.

What to ask

Who is my clinician, and what is their training in diabetes?
How will my CGM data be shared, and how often will it be reviewed?
How are insulin doses adjusted between visits?
How are labs ordered and where are they done?
How do you coordinate with my primary care, eye doctor, and podiatrist?
What happens if I have severe hypoglycemia at 2 a.m.?
What does this cost — visits, devices, medications, education?

When this is not enough

Diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state, severe hypoglycemia with altered consciousness, suspected diabetic foot infection, and diabetic eye complications are in-person or emergency situations. New diagnosis of type 1 diabetes is initially an in-person workup. Pregnancy with diabetes is a higher-acuity situation that is best managed with in-person obstetric and endocrine care, even if some visits remain remote. See when telehealth is not enough.

Diabetes remote management